Whole Genome Sequencing (Hongkong) Test at Chughtai Lab

Whole Genome Sequencing (Hongkong) at Chughtai Lab

Whole Genome Sequencing (WGS) represents the pinnacle of modern genomic medicine, offering an unparalleled, comprehensive analysis of an individual’s entire genetic blueprint. Unlike targeted genetic panels or whole exome sequencing, which only analyze specific genes or protein-coding regions, Whole Genome Sequencing decodes all 3 billion base pairs of the human genome. This includes both the coding regions (exons) and the non-coding regions (introns, promoters, and enhancers) that play a critical role in gene regulation and expression. By utilizing state-of-the-art Next-Generation Sequencing (NGS) technology, this advanced diagnostic test can identify a vast array of genetic variations, including single nucleotide variants (SNVs), small insertions and deletions (indels), copy number variations (CNVs), and complex structural rearrangements. The “Hongkong” designation for this test at Chughtai Lab signifies a strategic clinical collaboration with leading international genomic facilities in Hong Kong. This partnership ensures that patient samples collected across Pakistan are processed using world-class high-throughput sequencing platforms and analyzed using highly sophisticated bioinformatics pipelines and curated clinical databases. The diagnostic value of Whole Genome Sequencing is immense. It serves as a definitive diagnostic tool for patients with rare, complex, or undiagnosed medical conditions, often ending years of diagnostic uncertainty—a phenomenon known as the diagnostic odyssey. Furthermore, WGS provides critical insights into hereditary cancer risks, cardiovascular predispositions, neurological disorders, and pharmacogenomic profiles, which help clinicians tailor highly personalized treatment plans. By mapping the entire genome, Chughtai Lab empowers patients and healthcare providers with actionable genetic intelligence to guide lifelong medical management, preventive care, and family planning.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure the integrity of the genetic sample and the clinical utility of the Whole Genome Sequencing process. Patients undergoing this test at Chughtai Lab must adhere to the following guidelines:

• Informed Consent and Counseling: Because Whole Genome Sequencing reveals comprehensive genetic information, including potential secondary findings and carrier status for hereditary diseases, obtaining formal informed consent is mandatory. Pre-test genetic counseling with a qualified genetic counselor or specialist is highly recommended to help patients understand the implications of the results.
• Clinical Documentation: Patients must provide a detailed clinical history, including a comprehensive multi-generation family pedigree, previous diagnostic reports, and relevant laboratory or imaging results. This clinical context is vital for the bioinformatics team to interpret genetic variants accurately.
• No Fasting Required: Standard peripheral blood collection does not require fasting. Patients may eat and drink normally prior to the sample collection.
• Hydration: Staying well-hydrated is recommended to facilitate easier venipuncture.
• Transfusion History: Patients must inform the laboratory if they have received a blood transfusion within the last 30 days or if they have undergone a bone marrow transplant, as these procedures can introduce donor DNA and interfere with the accuracy of the sequencing results.

During the Procedure

The procedure for Whole Genome Sequencing is designed to be safe, efficient, and minimally invasive for the patient:

• Patient Identification and Verification: Upon arrival at a Chughtai Lab collection center, the patient’s identity is verified, and all clinical documentation and consent forms are meticulously reviewed.
• Sample Collection: A trained phlebotomist performs a standard venipuncture, typically drawing 3 to 5 mL of peripheral blood into a sterile EDTA tube. For infants or patients where blood collection is clinically challenging, alternative sample types such as saliva or buccal swabs may be utilized, subject to specific collection protocols.
• Barcoding and Chain of Custody: The sample tube is immediately labeled with a unique barcode to ensure strict tracking and maintain a secure chain of custody throughout the transport and testing phases.
• Logistics and Transport: The sample is prepared for secure, temperature-controlled international transport to the specialized genomic sequencing facility in Hong Kong.
• Laboratory Processing: At the partner laboratory, genomic DNA is extracted from the sample and subjected to rigorous quality control checks to evaluate purity and concentration.
• Next-Generation Sequencing (NGS): The high-quality DNA is fragmented, and a genomic library is prepared. The library is then sequenced on high-throughput NGS platforms, generating billions of short sequence reads.
• Bioinformatics and Interpretation: Advanced computational pipelines align the sequence reads to the human reference genome. Specialized clinical geneticists and bioinformaticians filter and analyze the identified variants, correlating them with the patient’s clinical phenotype to generate a highly detailed clinical report.

When is a Whole Genome Sequencing (Hongkong) Performed?

Diagnostic Evaluation of Rare and Undiagnosed Genetic Disorders

Many patients, particularly children, suffer from rare, complex, and multi-systemic disorders that elude standard diagnostic methods. When traditional laboratory tests, imaging, and single-gene panels fail to provide an answer, physicians recommend Whole Genome Sequencing. By analyzing the entire genome, WGS can pinpoint rare pathogenic mutations in novel or rarely characterized genes, providing a definitive diagnosis, ending the diagnostic odyssey, and allowing families to understand the natural history of the condition.

Identification of Hereditary Cancer Syndromes and Familial Risks

A strong family history of early-onset cancers, bilateral tumors, or multiple family members affected by the same type of cancer strongly suggests a hereditary cancer syndrome. Whole Genome Sequencing is performed to screen the entire genome for pathogenic germline variants in established cancer-susceptibility genes (such as BRCA1, BRCA2, TP53, and mismatch repair genes) as well as emerging risk genes. This information is crucial for implementing intensive surveillance, prophylactic interventions, and testing at-risk family members.

Investigation of Complex Neurodevelopmental and Neuromuscular Conditions

Neurological disorders, including unexplained developmental delays, severe autism spectrum disorders, intractable epilepsy, muscular dystrophies, and early-onset neurodegenerative conditions, often have a complex genetic basis. Physicians request WGS to identify causative genetic variants, which can help differentiate between look-alike syndromes, predict disease progression, and guide targeted therapeutic strategies, such as gene-specific therapies or clinical trial enrollment.

Cardiovascular and Cardiomyopathy Risk Profiling

Inherited cardiac conditions, such as hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular dysplasia, and channelopathies like Long QT syndrome, can lead to sudden cardiac death, often without warning. Whole Genome Sequencing is indicated for individuals with a family history of sudden unexplained death or those presenting with unexplained cardiac symptoms. Identifying a pathogenic variant allows for proactive clinical management, lifestyle modifications, and family screening.

Pharmacogenomics and Personalized Treatment Planning

An individual’s genetic makeup significantly influences how their body metabolizes and responds to various medications. Whole Genome Sequencing analyzes pharmacogenomic markers across the genome, providing valuable data on drug efficacy and the risk of adverse drug reactions. Clinicians use this information to personalize medication selection and dosages for psychiatric drugs, cardiovascular medications, pain management, and oncology therapies, ensuring safer and more effective treatment outcomes.

What Does a Whole Genome Sequencing (Hongkong) Detect?

Whole Genome Sequencing is an incredibly powerful diagnostic tool capable of detecting a wide spectrum of genetic variations across the entire genome. Specifically, this comprehensive analysis detects:

• Single nucleotide variants (SNVs) that alter protein structure or function.
• Small insertions and deletions (indels) that disrupt the genetic reading frame.
• Copy number variations (CNVs), including microdeletions and microduplications associated with developmental delay.
• Large-scale structural genomic rearrangements, such as translocations and inversions.
• Pathogenic mutations in high-risk hereditary cancer genes (e.g., BRCA1, BRCA2, PALB2, TP53).
• Genetic variants responsible for inherited cardiomyopathies and channelopathies.
• Inborn errors of metabolism, including lysosomal storage diseases and organic acidemias.
• Causative mutations for neurodevelopmental disorders, including severe autism and intellectual disability.
• Genetic markers for neuromuscular diseases, such as spinal muscular atrophy and muscular dystrophies.
• Pharmacogenomic alleles (e.g., in CYP2D6, CYP2C19, and CYP2C9) affecting drug metabolism.
• Mitochondrial DNA variants that can cause mitochondrial encephalomyopathies.
• Carrier status for autosomal recessive disorders, including beta-thalassemia, cystic fibrosis, and sickle cell anemia.
• Pathogenic variants in genes regulating connective tissue integrity (e.g., FBN1, COL3A1).
• Primary immunodeficiency disorders caused by single-gene defects.
• Splice-site mutations that lead to aberrant mRNA splicing and non-functional proteins.
• Deep intronic variants that affect gene expression by creating cryptic splice sites or altering regulatory elements.
• Variants of Uncertain Significance (VUS) that require further clinical and familial correlation.
• De novo mutations when comparing the patient’s genome with parental genomes (trio analysis).
• Aneuploidies and large chromosomal imbalances across all autosomes and sex chromosomes.
• Genetic predispositions to early-onset neurodegenerative diseases like Huntington’s disease.
• Mutations in genes associated with congenital endocrine disorders, such as congenital adrenal hyperplasia.
• Genetic variations linked to hereditary renal diseases, such as polycystic kidney disease.

Turnaround Time and Report Access at Chughtai Lab

Whole Genome Sequencing is a highly complex, multi-step molecular investigation that requires meticulous laboratory processing, high-throughput sequencing, and extensive bioinformatic analysis. Because patient samples are securely transported to premier genomic laboratories in Hong Kong for sequencing and then analyzed by a multidisciplinary team of bioinformaticians and clinical geneticists, the turnaround time for this test is typically 4 to 6 weeks. Chughtai Lab is committed to ensuring the highest standards of accuracy and clinical utility, which necessitates this thorough interpretation process. Once the comprehensive genomic report is finalized, patients and their referring physicians can access the results securely online. Reports can be downloaded directly from the official Chughtai Lab website or through the user-friendly Chughtai Lab mobile app using the unique patient registration number and password provided at the time of sample collection. Given the complexity of Whole Genome Sequencing reports, which contain vast amounts of genetic data, Chughtai Lab strongly advises patients to schedule a consultation with a clinical geneticist or their referring specialist to discuss the findings, understand their clinical implications, and formulate an appropriate medical management plan.

Whole Genome Sequencing (Hongkong) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Coding Regions (Exome)	No pathogenic or likely pathogenic variants identified; wild-type sequence.	Pathogenic or likely pathogenic single nucleotide variants (SNVs) or indels disrupting protein function.
Non-Coding Regions (Introns/Promoters)	No regulatory or deep intronic variants of clinical significance detected.	Pathogenic splice-site mutations or regulatory variants affecting gene expression.
Copy Number Variations (CNVs)	Normal diploid state across all chromosomes; no significant deletions or duplications.	Microdeletions or microduplications associated with developmental delay or syndromic features.
Structural Variants (SVs)	Absence of large-scale genomic rearrangements, inversions, or translocations.	Balanced or unbalanced translocations, inversions, or complex rearrangements disrupting critical genes.
Pharmacogenomic Profile	Standard or normal metabolizer status for key therapeutic drug classes.	Poor, intermediate, or ultra-rapid metabolizer variants (e.g., in CYP genes) altering drug response.
Carrier Screening Panel	Non-carrier status for tested severe autosomal recessive or X-linked conditions.	Heterozygous carrier of pathogenic variants for conditions like beta-thalassemia or cystic fibrosis.
Mitochondrial Genome	No pathogenic variants detected in the mitochondrial DNA sequence.	Pathogenic mitochondrial mutations associated with Leigh syndrome, MELAS, or LHON.
Variants of Uncertain Significance (VUS)	No VUS identified in genes matching the patient’s clinical phenotype.	Presence of one or more VUS requiring parental segregation testing or functional studies.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Whole Genome Sequencing (Hongkong)?

• Experienced Healthcare Professionals: Chughtai Lab features a dedicated team of highly qualified pathologists, molecular biologists, and laboratory technologists who ensure the highest standards of sample integrity and clinical oversight.
• International Collaboration: By partnering with premier genomic laboratories in Hong Kong, Chughtai Lab brings world-class Next-Generation Sequencing (NGS) technology and advanced bioinformatics pipelines to patients in Pakistan.
• Comprehensive Genomic Analysis: The test evaluates the entire genome, including coding and non-coding regions, providing an exhaustive genetic assessment that far exceeds standard genetic testing panels.
• Accredited Quality Standards: Chughtai Lab maintains rigorous quality control protocols and international benchmarks, ensuring that every step of the diagnostic process is highly accurate and reliable.
• Convenient Sample Collection: With an extensive network of diagnostic centers across Pakistan and a professional home sample collection service, patients can easily provide their samples in a comfortable environment.
• Secure and Confidential Reporting: Genetic data is highly sensitive; Chughtai Lab guarantees strict confidentiality and secure data management throughout the testing and reporting process.
• Easy Digital Report Access: Patients and physicians can conveniently access and download the comprehensive genomic reports online via the Chughtai Lab website or mobile app.
• Patient-Focused Care: Chughtai Lab is dedicated to supporting patients throughout their diagnostic journey, providing clear instructions, professional support, and reliable diagnostic insights to guide clinical decision-making.